The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

References

• Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67(Suppl 3):iii2–25.
   PubMed Web of Science ®Google Scholar
• Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. Br Med J 1998;316:1232–5.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, Evidence-based rheumatology, 1st edn. London: BMJ books, 2004.
   Google Scholar
• Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J 2009;181:787–96.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomised controlled trials. J Clin Epidemiol 1997;6:683–91.
   Google Scholar
• Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheum 2007;36:411–17.
   PubMed Web of Science ®Google Scholar
• Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003;62:316–21.
   PubMed Web of Science ®Google Scholar
• Altman DG. Confidence intervals for the number needed to treat. Br Med J 1998;317:1309–12.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PRISMA Group. J Clin Epidemiol 2009;62:1006–12.
   PubMed Web of Science ®Google Scholar
• Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis 2006;65:1602–7.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600–6.
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096–103.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807–16.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263–71. Erratum in: Arthritis Rheum 2005;52:3321.
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797–804.
   PubMed Web of Science ®Google Scholar
• Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41:1133–7.
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:964–75.
   PubMed Web of Science ®Google Scholar
• Emery P, Rigby W, Combe B, Latinis K, Szczepański LJ, Roschmannet RA, Efficacy and safety of rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results of a phase III randomized controlled study (SERENE). Arthritis Rheum 2008;Suppl 58:S302.
   Google Scholar
• Rubbert-Roth A, Tak PP, Bombardieri S, Zerbini C, Tremblay J-L, Carreño L, Efficacy and safety of various dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). Arthritis Rheum 2008;Suppl 58:S301.
   Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12–19.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817–29. Erratum in: Arthritis Rheum 2008;58:887.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865–76.
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29. Erratum in: Arthritis Rheum 2009;60:1249.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 2009;68:789–96.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
   PubMed Web of Science ®Google Scholar